$CMPS
COMPASS Pathways plc

2024 Q2 Form 10-Q Financial Statement

#000162828024021351 Filed on May 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.25M $11.23M $9.192M
YoY Change 48.67% 6.29% -10.1%
% of Gross Profit
Research & Development $29.07M $24.90M $27.14M
YoY Change 46.68% 30.82% 37.11%
% of Gross Profit
Depreciation & Amortization $63.00K $61.00K -$102.0K
YoY Change -42.73% 27.08% -206.25%
% of Gross Profit
Operating Expenses $43.32M $38.57M $36.33M
YoY Change 47.33% 21.34% 21.03%
Operating Profit -$43.32M -$38.57M
YoY Change 32.63% 21.34%
Interest Expense $1.521M $1.098M $498.0K
YoY Change 10.54% -59.11% -113.97%
% of Operating Profit
Other Income/Expense, Net $5.397M $3.608M $5.769M
YoY Change 71.5% -53.2% 17.18%
Pretax Income -$37.93M -$34.97M -$32.14M
YoY Change 34.77% 45.22% 4.23%
Income Tax $176.0K $222.0K $394.0K
% Of Pretax Income
Net Earnings -$38.10M -$35.19M -$32.53M
YoY Change 34.47% 45.35% 5.19%
Net Earnings / Revenue
Basic Earnings Per Share -$560.00 -$0.55
Diluted Earnings Per Share -$560.00 -$0.55 -$0.52
COMMON SHARES
Basic Shares Outstanding 68.38M shares 64.23M shares 61.90M shares
Diluted Shares Outstanding 68.37M shares 64.22M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $228.6M $262.9M $220.2M
YoY Change 54.23% 124.49% 53.76%
Cash & Equivalents $228.6M $262.9M $220.2M
Short-Term Investments
Other Short-Term Assets $2.699M $1.719M $1.895M
YoY Change -87.92% 15.37% 100.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $265.1M $295.5M $261.3M
YoY Change 36.93% 76.08% 36.34%
LONG-TERM ASSETS
Property, Plant & Equipment $3.179M $359.0K $423.0K
YoY Change -39.63% -41.34% -31.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $469.0K $469.0K
YoY Change 0.0% 0.0%
Other Assets $6.239M $6.097M $7.049M
YoY Change -40.57% 2775.94% 2055.66%
Total Long-Term Assets $13.44M $13.48M $14.69M
YoY Change -17.21% 145.77% 160.34%
TOTAL ASSETS
Total Short-Term Assets $265.1M $295.5M $261.3M
Total Long-Term Assets $13.44M $13.48M $14.69M
Total Assets $278.5M $309.0M $276.0M
YoY Change 32.74% 78.29% 39.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.195M $9.342M $5.892M
YoY Change 313.47% 141.08% 23.76%
Accrued Expenses $13.83M $8.513M $12.69M
YoY Change 37.05% 26.93% 24.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.03M $19.40M $19.60M
YoY Change 72.42% 72.4% 25.7%
LONG-TERM LIABILITIES
Long-Term Debt $29.43M $29.09M $28.76M
YoY Change 4.66%
Other Long-Term Liabilities $799.0K $1.339M $1.882M
YoY Change -68.53% 225.0% 350.24%
Total Long-Term Liabilities $30.23M $30.43M $30.64M
YoY Change -1.4% 7285.68% 7229.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.03M $19.40M $19.60M
Total Long-Term Liabilities $30.23M $30.43M $30.64M
Total Liabilities $52.26M $49.83M $50.24M
YoY Change 20.31% 327.15% 213.74%
SHAREHOLDERS EQUITY
Retained Earnings -$452.9M -$414.8M -$379.6M
YoY Change 44.37% 45.36% 45.36%
Common Stock $699.0K $699.0K $635.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $226.3M $259.2M $225.7M
YoY Change
Total Liabilities & Shareholders Equity $278.5M $309.0M $276.0M
YoY Change 32.74% 78.29% 39.89%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$38.10M -$35.19M -$32.53M
YoY Change 34.47% 45.35% 5.19%
Depreciation, Depletion And Amortization $63.00K $61.00K -$102.0K
YoY Change -42.73% 27.08% -206.25%
Cash From Operating Activities -$34.42M -$20.83M -$27.78M
YoY Change 38.7% -24.87% -38.67%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$4.000K
YoY Change -100.0% -100.0% -103.74%
Acquisitions
YoY Change
Other Investing Activities $0.00 $2.000K
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 -$4.000K
YoY Change -100.0% -100.0% -96.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 210.0K $63.51M 41.00K
YoY Change -99.62% 5786.19% -93.58%
NET CHANGE
Cash From Operating Activities -34.42M -$20.83M -27.78M
Cash From Investing Activities 0.000 $0.00 -4.000K
Cash From Financing Activities 210.0K $63.51M 41.00K
Net Change In Cash -34.21M $42.64M -27.74M
YoY Change -209.99% -263.95% -38.04%
FREE CASH FLOW
Cash From Operating Activities -$34.42M -$20.83M -$27.78M
Capital Expenditures $0.00 $0.00 -$4.000K
Free Cash Flow -$34.42M -$20.83M -$27.78M
YoY Change 38.6% -24.95% -38.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Prepaid Taxes
PrepaidTaxes
1123000 usd
CY2023Q4 us-gaap Prepaid Taxes
PrepaidTaxes
1123000 usd
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
31115000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
39535000 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
295515000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
261296000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3722000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4306000 usd
CY2024Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3659000 usd
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3336000 usd
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6097000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7049000 usd
CY2024Q1 us-gaap Assets
Assets
308993000 usd
CY2023Q4 us-gaap Assets
Assets
275987000 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
9342000 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34965000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-35187000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5892000 usd
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
7680000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
11301000 usd
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
29090000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
28757000 usd
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
68342534 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
61943471 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61943471 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61943471 shares
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
38573000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
31788000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-38573000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-31788000 usd
CY2024Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2388000 usd
CY2023Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
709000 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
1098000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
0 usd
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-783000 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2685000 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3608000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7710000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24078000 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
222000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
130000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-35187000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24208000 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64222178 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64222178 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42725863 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42725863 shares
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-35187000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24208000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-36000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-578000 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35223000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24786000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
181280000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1188000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
109000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4071000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-578000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
161644000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
225744000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
220000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26219000 usd
CY2024Q1 cmps Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
37258000 usd
CY2024Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
185000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5129000 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-36000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-35187000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
259162000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-35187000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24208000 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
61000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
48000 usd
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
333000 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-230000 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
2107000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5129000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4071000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
555000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
539000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-8136000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1484000 usd
CY2024Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
322000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-129000 usd
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-837000 usd
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
44000 usd
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-545000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-478000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3517000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-973000 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3572000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3216000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20828000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27723000 usd
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29000 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26219000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1188000 usd
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
37258000 usd
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
CY2024Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
185000 usd
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
109000 usd
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
220000 usd
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63512000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1079000 usd
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-45000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
666000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42639000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26007000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
220638000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143381000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
263277000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117374000 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
765000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
262888000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117103000 usd
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
389000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
271000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
263277000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117374000 usd
CY2021Q4 cmps Number Of Ordinary Shares Conversion Ratio
NumberOfOrdinarySharesConversionRatio
1
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-35200000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24200000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-414800000 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
262900000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and the research and development tax credit. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></div>
CY2024Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
500000 usd
CY2024Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Cumulative Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount
0 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places cash and cash equivalents in diversified and established financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company has cash and cash equivalents in excess of the FDIC insured limit. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements</span></div>
CY2024Q1 cmps Number Of Geographic Regions
NumberOfGeographicRegions
2 region
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 cmps Research And Development Expenditures Tax Credit Connected Parties Maximum Percentage Of Total Claim
ResearchAndDevelopmentExpendituresTaxCreditConnectedPartiesMaximumPercentageOfTotalClaim
0.15
CY2023Q3 cmps Number Of Ordinary Shares Conversion Ratio
NumberOfOrdinarySharesConversionRatio
1
CY2024Q1 cmps Research And Development Tax Credit Current
ResearchAndDevelopmentTaxCreditCurrent
16155000 usd
CY2023Q4 cmps Research And Development Tax Credit Current
ResearchAndDevelopmentTaxCreditCurrent
27877000 usd
CY2024Q1 cmps Prepaid Expense Research And Development Current
PrepaidExpenseResearchAndDevelopmentCurrent
10538000 usd
CY2023Q4 cmps Prepaid Expense Research And Development Current
PrepaidExpenseResearchAndDevelopmentCurrent
6826000 usd
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1374000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1885000 usd
CY2024Q1 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1329000 usd
CY2023Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1052000 usd
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1719000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1895000 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
31115000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
39535000 usd
CY2024Q1 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
14600000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
11301000 usd
CY2024Q1 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
3300000 usd
CY2024Q1 cmps Options Number Of Shares Available For Purchase Percent Of Principal Amount Of Term Loan Advances
OptionsNumberOfSharesAvailableForPurchasePercentOfPrincipalAmountOfTermLoanAdvances
0.025
CY2024Q1 cmps Prepaid Research And Development Noncurrent
PrepaidResearchAndDevelopmentNoncurrent
5267000 usd
CY2023Q4 cmps Prepaid Research And Development Noncurrent
PrepaidResearchAndDevelopmentNoncurrent
5955000 usd
CY2024Q1 us-gaap Other Investments
OtherInvestments
469000 usd
CY2023Q4 us-gaap Other Investments
OtherInvestments
469000 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
359000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
423000 usd
CY2024Q1 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
2000 usd
CY2023Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
202000 usd
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6097000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7049000 usd
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3119000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7069000 usd
CY2024Q1 cmps Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1487000 usd
CY2023Q4 cmps Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2117000 usd
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1247000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1077000 usd
CY2024Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
544000 usd
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0 usd
CY2024Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
280000 usd
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
13000 usd
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1003000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1025000 usd
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
7680000 usd
CY2024Q1 cmps Options Exercisable Number
OptionsExercisableNumber
94222 shares
CY2024Q1 cmps Options Exercisable Fair Value
OptionsExercisableFairValue
700000 usd
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000 usd
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000 usd
CY2024Q1 cmps Long Term Debt End Of Term Charge
LongTermDebtEndOfTermCharge
1425000 usd
CY2023Q4 cmps Long Term Debt End Of Term Charge
LongTermDebtEndOfTermCharge
1425000 usd
CY2024Q1 cmps Long Term Debt Including End Of Term Charge
LongTermDebtIncludingEndOfTermCharge
31425000 usd
CY2023Q4 cmps Long Term Debt Including End Of Term Charge
LongTermDebtIncludingEndOfTermCharge
31425000 usd
CY2024Q1 cmps Debt Instrument Paid In Kind Interest Payable
DebtInstrumentPaidInKindInterestPayable
324000 usd
CY2023Q4 cmps Debt Instrument Paid In Kind Interest Payable
DebtInstrumentPaidInKindInterestPayable
216000 usd
CY2024Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2659000 usd
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2884000 usd
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
29090000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
28757000 usd
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0 usd
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
6572000 usd
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
14166000 usd
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
10687000 usd
CY2024Q1 cmps Long Term Debt Including End Of Term Charge
LongTermDebtIncludingEndOfTermCharge
31425000 usd
CY2024Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
1100000 usd
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
0 usd
CY2024Q1 cmps Cash Dividend Declared Or Paid During Period
CashDividendDeclaredOrPaidDuringPeriod
0 usd
CY2021Q4 cmps Number Of Ordinary Shares Conversion Ratio
NumberOfOrdinarySharesConversionRatio
1
CY2023Q3 cmps Number Of Ordinary Shares Conversion Ratio
NumberOfOrdinarySharesConversionRatio
1
CY2024Q1 cmps Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice
10.89
CY2023Q1 cmps Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAverageExercisePrice
10.85
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
87000 usd
CY2024Q1 us-gaap Lease Cost
LeaseCost
638000 usd
CY2023Q1 us-gaap Lease Cost
LeaseCost
660000 usd
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
628000 usd
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5129000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4071000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6969328 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.14
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M23D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
14070000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2073529 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.38
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
86510 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.48
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
768841 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
17.16
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8187506 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.17
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M19D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
15288000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3780781 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.77
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M15D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11553000 usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
4406725 shares
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
11.66
CY2024Q1 cmps Share Based Compensation Arrangement By Share Based Payment Award Nonvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedWeightedAverageRemainingContractualTerm
P9Y14D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
3735000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
700000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.03
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.27
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
39000000.0 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
42300000 usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y5M12D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8757
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8712
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0392
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0347
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-35187000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24208000 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-35187000 usd
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35187000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24208000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24208000 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64222178 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64222178 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42725863 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42725863 shares
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21254085 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7442071 shares
CY2023Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2023Q4 cmps Lessee Operating Lease Annual Increase In Lease Payments
LesseeOperatingLeaseAnnualIncreaseInLeasePayments
0.035
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
700000 usd
CY2023Q4 cmps Lessee Operating Lease Noncancelable Term
LesseeOperatingLeaseNoncancelableTerm
P2Y
CY2023Q4 cmps Lessee Operating Lease Termination Period Minimum Lease Term
LesseeOperatingLeaseTerminationPeriodMinimumLeaseTerm
P2Y
CY2023Q4 cmps Lessee Operating Lease Termination Fee Period
LesseeOperatingLeaseTerminationFeePeriod
P3M
CY2024Q1 cmps Lease Deposit Payments
LeaseDepositPayments
0 gbp
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
638000 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
573000 usd
CY2024Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
562000 usd
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
102000 usd
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0850
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0601
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1861000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1809000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
227000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
96000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3993000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
274000 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3719000 usd
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001628280-24-021351-index-headers.html Edgar Link pending
0001628280-24-021351-index.html Edgar Link pending
0001628280-24-021351.txt Edgar Link pending
0001628280-24-021351-xbrl.zip Edgar Link pending
cmps-20240331.htm Edgar Link pending
cmps-20240331.xsd Edgar Link pending
cmps-q1x24xex311ceo302cert.htm Edgar Link pending
cmps-q1x24xex312cfo302cert.htm Edgar Link pending
cmps-q1x24xex321ceoxcfosec.htm Edgar Link pending
exhibit101mattemployment.htm Edgar Link pending
exhibit101mattemployment001.jpg Edgar Link pending
exhibit101mattemployment002.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
cmps-20240331_def.xml Edgar Link unprocessable
cmps-20240331_lab.xml Edgar Link unprocessable
cmps-20240331_htm.xml Edgar Link completed
cmps-20240331_pre.xml Edgar Link unprocessable
0001628280-24-021351-index-headers.html Edgar Link pending
0001628280-24-021351-index.html Edgar Link pending
0001628280-24-021351.txt Edgar Link pending
0001628280-24-021351-xbrl.zip Edgar Link pending
cmps-20240331.htm Edgar Link pending
cmps-20240331.xsd Edgar Link pending
cmps-20240331_cal.xml Edgar Link unprocessable
cmps-20240331_def.xml Edgar Link unprocessable
cmps-20240331_lab.xml Edgar Link unprocessable
cmps-20240331_pre.xml Edgar Link unprocessable
cmps-20240331_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ukemploymentagreementkab.htm Edgar Link pending
ukemploymentagreementkab001.jpg Edgar Link pending
ukemploymentagreementkab002.jpg Edgar Link pending
ukemploymentagreementkab003.jpg Edgar Link pending
ukemploymentagreementkab004.jpg Edgar Link pending
ukemploymentagreementkab005.jpg Edgar Link pending
ukemploymentagreementkab006.jpg Edgar Link pending
ukemploymentagreementkab007.jpg Edgar Link pending
ukemploymentagreementkab008.jpg Edgar Link pending
ukemploymentagreementkab009.jpg Edgar Link pending
ukemploymentagreementkab010.jpg Edgar Link pending
ukemploymentagreementkab011.jpg Edgar Link pending
ukemploymentagreementkab012.jpg Edgar Link pending
ukemploymentagreementkab013.jpg Edgar Link pending
ukemploymentagreementkab014.jpg Edgar Link pending
ukemploymentagreementkab015.jpg Edgar Link pending
ukemploymentagreementkab016.jpg Edgar Link pending
ukemploymentagreementkab017.jpg Edgar Link pending
ukemploymentagreementkab018.jpg Edgar Link pending
ukemploymentagreementkab019.jpg Edgar Link pending
ukemploymentagreementkab020.jpg Edgar Link pending
ukemploymentagreementkab021.jpg Edgar Link pending
ukemploymentagreementkab022.jpg Edgar Link pending
ukemploymentagreementkab023.jpg Edgar Link pending
ukemploymentagreementkab024.jpg Edgar Link pending
ukemploymentagreementkab025.jpg Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ukemploymentagreementkab.htm Edgar Link pending
ukemploymentagreementkab001.jpg Edgar Link pending
ukemploymentagreementkab002.jpg Edgar Link pending
ukemploymentagreementkab003.jpg Edgar Link pending
ukemploymentagreementkab004.jpg Edgar Link pending
ukemploymentagreementkab005.jpg Edgar Link pending
ukemploymentagreementkab006.jpg Edgar Link pending
ukemploymentagreementkab007.jpg Edgar Link pending
ukemploymentagreementkab008.jpg Edgar Link pending
ukemploymentagreementkab009.jpg Edgar Link pending
ukemploymentagreementkab010.jpg Edgar Link pending
ukemploymentagreementkab011.jpg Edgar Link pending
ukemploymentagreementkab012.jpg Edgar Link pending
ukemploymentagreementkab013.jpg Edgar Link pending
ukemploymentagreementkab014.jpg Edgar Link pending
ukemploymentagreementkab015.jpg Edgar Link pending
ukemploymentagreementkab016.jpg Edgar Link pending
ukemploymentagreementkab017.jpg Edgar Link pending
ukemploymentagreementkab018.jpg Edgar Link pending
ukemploymentagreementkab019.jpg Edgar Link pending
ukemploymentagreementkab020.jpg Edgar Link pending
ukemploymentagreementkab021.jpg Edgar Link pending
ukemploymentagreementkab022.jpg Edgar Link pending
ukemploymentagreementkab023.jpg Edgar Link pending
ukemploymentagreementkab024.jpg Edgar Link pending
ukemploymentagreementkab025.jpg Edgar Link pending
cmps-q1x24xex311ceo302cert.htm Edgar Link pending
cmps-q1x24xex312cfo302cert.htm Edgar Link pending
cmps-q1x24xex321ceoxcfosec.htm Edgar Link pending
exhibit101mattemployment.htm Edgar Link pending
exhibit101mattemployment001.jpg Edgar Link pending
exhibit101mattemployment002.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
cmps-20240331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable